Moderna ($MRNA) stock jumped 17% on Thursday, fueled by speculation of potential buyout talks amid concerns over declining ...
Zacks Investment Research on MSN
Earnings Preview: Moderna (MRNA) Q3 Earnings Expected to Decline
The market expects Moderna (MRNA) to deliver a year-over-year decline in earnings on lower revenues when it reports results ...
Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...
The company’s portfolio includes two products: Covid-19 vaccine and RSV vaccine (approved only in May 2024). However the company does have a promising pipeline. Moderna has shown promising clinical ...
Moderna (NASDAQ:MRNA – Free Report) had its price target trimmed by JPMorgan Chase & Co. from $33.00 to $26.00 in a report issued on Thursday,Benzinga reports. The firm currently has an underweight ...
We just received data on a new analyst forecast for $MRNA. Dimple Gosai from B of A Securities set a price target of 25.0 for MRNA. To track analyst ratings and price ...
The biotech's innovative qualities will come in handy. Long gone are the days when Moderna ( MRNA 2.66%) would generate over $18 billion in annual sales from its COVID-19 vaccine. Over the past couple ...
Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven ...
Moderna Inc (NASDAQ:MRNA) shares are flat Wednesday morning after a nearly 5% surge on Tuesday. Here’s what investors need to know. What To Know: Tuesday’s rally was driven by the release of positive ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback